Clinical Trial

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-07 -> 2027-07 2026-07-19
minor Completion pushed: 2027-07 -> 2028-07 2026-07-19
Trial Details
NCT Number NCT04363164
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: United States Department of Defense
Conditions Castration Resistant Metastatic Prostate Cancer
Enrollment 150 participants
Start Date 2020-08-19
Primary Completion 2027-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-17